Taliglucerase alfa
- Generic Name
- Taliglucerase alfa
- Brand Names
- Elelyso
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 37228-64-1
- Unique Ingredient Identifier
- N69L6LM4QU
- Background
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
- Indication
For the treatment of adult Type 1 Gaucher disease.
- Associated Conditions
- Gaucher Disease, Type 1, Gaucher Disease, Type III
- Associated Therapies
- -
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
Protalix BioTherapeutics achieved significant milestones in 2024, including EMA validation for a less frequent dosing regimen of pegunigalsidase alfa for Fabry disease, and progress in PRX-115 clinical trials for uncontrolled gout. The company also repaid all outstanding convertible notes, becoming debt-free, and maintained full operations despite regional conflicts.
Self-Sustaining Rise to Lead in Renal Rare Disease
Protalix Biotherapeutics announced 3Q24 financial results, with $18M revenue (+74% YoY), driven by Chiesi revenues. Net income was $3.2M, or $0.03 per share. PRX-115 Phase I trial in gout completed, showing dose-dependent urate reduction and safety. Phase II planned for 2H25.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath